Cellebrite DI (CLBT)vsZepp Health Corp (ZEPP)
CLBT
Cellebrite DI
$12.71
+0.24%
TECHNOLOGY · Cap: $3.17B
ZEPP
Zepp Health Corp
$17.47
+4.55%
TECHNOLOGY · Cap: $247.54M
Smart Verdict
WallStSmart Research — data-driven comparison
Cellebrite DI generates 84% more annual revenue ($475.68M vs $258.90M). CLBT leads profitability with a 16.5% profit margin vs -15.5%. CLBT earns a higher WallStSmart Score of 48/100 (D+).
CLBT
Hold48
out of 100
Grade: D+
ZEPP
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.2%
Fair Value
$11.96
Current Price
$12.71
$0.75 premium
Margin of Safety
+48.6%
Fair Value
$46.70
Current Price
$17.47
$29.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
18.1% revenue growth
Reasonable price relative to book value
Revenue surging 43.0% year-over-year
Areas to Watch
1.8% earnings growth
Distress zone — elevated risk
Weak financial health signals
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of -17.2% — below average capital efficiency
Earnings declined 68.1%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : CLBT
The strongest argument for CLBT centers on Revenue Growth. Profitability is solid with margins at 16.5% and operating margin at 16.2%. Revenue growth of 18.1% demonstrates continued momentum.
Bull Case : ZEPP
The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.
Bear Case : CLBT
The primary concerns for CLBT are EPS Growth, Altman Z-Score, Piotroski F-Score. A P/E of 41.0x leaves little room for execution misses.
Bear Case : ZEPP
The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
CLBT profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.
ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.
ZEPP is growing revenue faster at 43.0% — sustainability is the question.
Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CLBT scores higher overall (48/100 vs 41/100), backed by strong 16.5% margins and 18.1% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cellebrite DI
TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA
Cellebrite DI Ltd. provides digital intelligence solutions for the public and private sectors globally. The company is headquartered in Petah Tikva, Israel.
Zepp Health Corp
TECHNOLOGY · CONSUMER ELECTRONICS · China
Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.
Compare with Other SOFTWARE - INFRASTRUCTURE Stocks
Want to dig deeper into these stocks?